Chemotherapy drugs are linked to severe vitamin D deficiency Healthy Holisic Living
- Breast Cancer chemotherapy 2.7 X more likely to be successful if not vitamin D deficient – Dec 2017
- Breast Cancer Chemotherapy dropped Vitamin D levels by 6 nanograms – Nov 2015
- Chemotherapy might be augmented with Vitamin D – Jan 2017
- Vitamin D levels dropped 3 ng during cancer chemotherapy – May 2012
- Chemotheraphy not work as well with low Vitamin D (colon cancer this time) – Aug 2018
- Chemotherapy might be amplified by vitamin D has the following chart and lots of details
Vitamin D is critically important for cancer patients in surviving their disease longer. Now, researchers have discovered that several chemotherapy drugs used to treat cancer may also cause severe vitamin D deficiency in patients. More disturbing is that attempts to give such patients supplemental vitamin D have met with mixed results, unless very high doses are applied. If these surprise findings are more widely applicable, they could provide new explanations for the extremely negative side effects of chemotherapy drugs.
It is well established that cancer patients have lower levels of vitamin D than the general public, but the relationship between vitamin D status and severity (stage) of cancer among patients remains unclear. It was exactly this link that oncologists at the Roswell Park Cancer Institute were researching when they unexpectedly discovered that the strongest risk factor for severe vitamin D deficiency was the use of chemotherapy drugs. Patients taking chemo (any of the three regimens being used) were 400% more likely to show severely depressed levels of the vitamin (less than 15 ng/ml) compared to those not on chemo (multivariate analysis of 315 patients). This is problematic, as one recent study showed that colon cancer patients with the lowest levels of vitamin D had a significantly greater risk of death compared to those with higher levels (hazard ratio = 1.92, lowest to highest quartile).
Not long after the results from the Roswell Park Cancer Institute were published, French researchers announced similar findings, but this time for breast cancer patients. Before treatment, 79.5% of their patients were insufficient for vitamin D (levels below 30 ng/ml), but 97.4% were insufficient after treatment (with neoadjuvant chemotherapy). Chemotherapy had caused the patients’ median vitamin D level to drop from 21.3 ng/ml to 14.7 ng/ml. As with colon cancer, lower vitamin D levels among breast cancer patients are correlated with reduced survival.
Research on maintaining vitamin D levels during chemotherapy treatment is still in early stages. Doctors at the Roswell Park Cancer Institute tested 2000 IU/day of supplemental vitamin D given to their colon cancer patients in a randomized trial. The average level of vitamin D for all patients at the start of the trial was 17.5 ng/ml. After six months of supplementation, this rose to a healthy 37.5 mg/ml for non-chemotherapy patients, but to only 29 mg/ml for patients on chemo, which is still insufficient. A similar trial was run with breast cancer patients, using low dose (1000 IU/day) or high dose (50,000 IU once per week). Patients started the trial with an average of 27.5 mg/ml. On the low dose, patients’ levels increased by only 9.4 mg/ml. However, the high dose increased patients’ vitamin D by 24.3 ng/ml, which brought their levels into a healthy range. These trials confirmed that chemotherapy may reduce a patient’s ability to utilize supplemental vitamin D, requiring them to take much higher doses than normal to achieve sufficiency.
The mechanisms by which chemotherapy drugs lower vitamin D in cancer patients remain unclear, but could include decreased absorption via subclinical mucositis or increased metabolism of vitamin D via the activation of enzymes such as CYP3A4. Until further research is completed, there is a risk that most (if not all) chemotherapy drugs may depress patients’ vitamin D levels. Cancer patients taking these drugs should therefore consider monitoring their vitamin D status throughout the treatment period as well as aggressive supplementation to maintain adequate levels which are associated with a better prognosis.
Vitamin D may sound like a vitamin, but it acts more like a hormone with receptor sites on healthy cells and even more on cancer cells. According to Canceractive.com there are three of the areas in which it acts:
The Boston Medical School has completed a great many research studies on vitamin D. Read the following statement from their Professor Hollick, “If women obtained adequate levels of vitamin D there would be 25 per cent less deaths from breast cancer.
Hollick is not alone in stressing the importance for women and breast cancer. St Georges Hospital in London calculated from their studies that women with low levels of vitamin D in their breast tissue have a 354 per cent greater risk of breast cancer. Translated into English this means they have 4 and a half times the breast cancer risk.
As you will see below, when it comes to fighting cancer, there seems little doubt about the virtues of this vitamin. Indeed many experts believe it is more like a hormone having receptor sites on both the cell and nuclear membranes – especially in cancer cells! According to research from the University of Copenhagen in 2010, when T-lymphocytes of the immune system come across a pathogen, the first thing they do is bind to a vitamin D molecule to ´activate´ themselves.
Recent studies covered in Cancer Watch suggest that the action of vitamin D is enhanced by vitamin K. Most adults are increasingly short of both D and K vitamins.
2012 research from the University of Carolina showed that children with low blood levels of vitamin D were more likely to become critically ill.
Research published in the Journal of Cell Biology November 17, 2008; 183(4):697-710 has shown that vitamin D can adjust almost everything in the cancer cell, from its genetic messaging to its cytoskeleton. It can switch genes on and off, and it can reduce cell division, and it can calm the cancer cells so that they settle rather than spread. It seems vitamin D can actually return a cancer cell to a normal and healthy state. One pathway seems to control everything. That is a very important set of findings.
But if you are in any doubt about its potential, then the pharmaceutical companies are certainly not. For example, Memorial Sloan-Kettering were involved in a Phase III clinical trial where a synthetically made, concentrated form of vitamin D, called Asentar, significantly improved patient survival times. It has enormous potential said Dr Howard Scher, team leader. Unfortunately, politics took their toll on the trial – but that´s another story.
!!!!Sources for this article include:
Ethan Evers began researching natural medicine when a family member used it to hold her cancer at bay for years before finally succumbing to the terrible disease. Since then, Ethan has watched the science behind natural medicine for cancer progress at an unbelievable rate—and be almost completely ignored by the mass media and conventional medicine. Despite an ever-growing mass of peer-reviewed research studies and ongoing clinical trials on natural remedies, the public remains under-informed (if not misinformed) about non-toxic, low cost treatments which may be able to treat cancer. More importantly, these same natural remedies may sharply reduce the risk of developing cancer in the first place.